These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18283451)

  • 21. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes.
    Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R
    J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.
    Kegeles LS; Zea-Ponce Y; Abi-Dargham A; Rodenhiser J; Wang T; Weiss R; Van Heertum RL; Mann JJ; Laruelle M
    Synapse; 1999 Mar; 31(4):302-8. PubMed ID: 10051112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study.
    Lomeña F; Catafau AM; Parellada E; Bernardo M; Font M; Gutiérrez F; Pavía J
    Psychopharmacology (Berl); 2004 Mar; 172(2):165-9. PubMed ID: 14624330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion.
    Martinez D; Greene K; Broft A; Kumar D; Liu F; Narendran R; Slifstein M; Van Heertum R; Kleber HD
    Am J Psychiatry; 2009 Oct; 166(10):1170-7. PubMed ID: 19723785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT.
    Ichise M; Fujita M; Seibyl JP; Verhoeff NP; Baldwin RM; Zoghbi SS; Rajeevan N; Charney DS; Innis RB
    J Nucl Med; 1999 Nov; 40(11):1902-12. PubMed ID: 10565788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous 99mTc and 123I dual-isotope brain striatal phantom single photon emission computed tomography: validation of 99mTc-TRODAT-1 and 123I-IBZM simultaneous dopamine system brain imaging.
    Kao PF; Wey SP; Yang AS
    Kaohsiung J Med Sci; 2009 Nov; 25(11):601-7. PubMed ID: 19858039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SPECT imaging of striatal dopamine release after amphetamine challenge.
    Laruelle M; Abi-Dargham A; van Dyck CH; Rosenblatt W; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Charney DS; Hoffer PB; Kung HF
    J Nucl Med; 1995 Jul; 36(7):1182-90. PubMed ID: 7790942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
    Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
    Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Abi-Dargham A; Kegeles LS; Zea-Ponce Y; Mawlawi O; Martinez D; Mitropoulou V; O'Flynn K; Koenigsberg HW; Van Heertum R; Cooper T; Laruelle M; Siever LJ
    Biol Psychiatry; 2004 May; 55(10):1001-6. PubMed ID: 15121484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.
    Yang YK; Yu L; Yeh TL; Chiu NT; Chen PS; Lee IH;
    Am J Psychiatry; 2004 Aug; 161(8):1496-8. PubMed ID: 15285982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
    Klimke A; Larisch R; Janz A; Vosberg H; Müller-Gärtner HW; Gaebel W
    Psychiatry Res; 1999 Apr; 90(2):91-101. PubMed ID: 10482381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms.
    Pogarell O; Koch W; Karch S; Dehning S; Müller N; Tatsch K; Poepperl G; Möller HJ
    Pharmacopsychiatry; 2012 May; 45 Suppl 1():S36-41. PubMed ID: 22565233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients.
    Guardia J; Catafau AM; Batlle F; Martín JC; Segura L; Gonzalvo B; Prat G; Carrió I; Casas M
    Am J Psychiatry; 2000 Jan; 157(1):127-9. PubMed ID: 10618027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.
    Castner SA; al-Tikriti MS; Baldwin RM; Seibyl JP; Innis RB; Goldman-Rakic PS
    Neuropsychopharmacology; 2000 Jan; 22(1):4-13. PubMed ID: 10633485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.